Organization
Georgetown Lombardi Comprehensive Cancer Center
13 abstracts
Abstract
A phase III trial evaluating addition of adjuvant chemotherapy to ovarian function suppression + endocrine therapy in premenopausal women with pN0-1, HR+/HER2- breast cancer (BC) and oncotype recurrence score (RS) ≤25 (OFSET): NRG-BR009.Org: Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, MedStar Health, University of Pittsburgh School of Public Health, University of Pittsburgh Medical Center (UPMC),
Abstract
INAVO122: A phase III study of maintenance inavolisib or placebo + pertuzumab + trastuzumab following induction with pertuzumab + trastuzumab + a taxane in patients (pts) with PIK3CA-mutated, HER2-positive advanced breast cancer (HER2+ aBC).Org: Genentech, Product Development Data Science, F. Hoffmann-La Roche Ltd., F. Hoffmann-La Roche Ltd, Roche Products Ltd., Product Development Oncology, F. Hoffmann-La Roche Ltd.,
Abstract
Immune-related adverse event prediction and influential factor identification.Org: Georgetown University Medical Center, Washington, DC, Georgetown Lombardi Comprehensive Cancer Center, Memorial Sloan Kettering Cancer Center, New York, NY,
Abstract
Association of Agent Orange and myeloproliferative neoplasms, thrombosis, and bleeding among veterans.Org: Georgetown Lombardi Comprehensive Cancer Center, George Washington University Hospital, George Washington University Milken Institute School of Public Health, Washington DC VA Medical Center, George Washington University School of Medicine and Health Sciences,
Abstract
Phase II clinical trial of olaparib plus pembrolizumab in the treatment of patients with advanced biliary tract cancer.Org: MedStar Georgetown University Hospital, MedStar Harbor Hospital, Georgetown University Medical School, Georgetown Lombardi Comprehensive Cancer Center, The Ruesch Center for the Cure of Gastrointestinal Cancers,
Abstract
Phase I study of NEROFE and doxorubicin in KRAS-mutated ST2-positive solid tumors.Org: Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University Medical School, Georgetown Lombardi Comprehensive Cancer Center, Georgetown - Lombardi Comprehensive Cancer Center,
Abstract
LITESPARK-024: Randomized phase 1/2 study of belzutifan with or without palbociclib for treatment of advanced renal cell carcinoma (RCC).Org: Beth Israel Deaconess Medical Center, Rambam Health Care Campus, Huntsman Cancer Institute, Georgetown Lombardi Comprehensive Cancer Center, Merck & Co., Inc.,
Abstract
Interim analysis of a phase II study of nivolumab/ipilimumab plus cabozantinib in patients with unresectable advanced melanoma.Org: Georgetown - Lombardi Comprehensive Cancer Center, John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ, Washington Cancer Institute/Georgetown-Lombardi Comprehensive Cancer Center, Medstar Franklin Square Medical Center, Georgetown Lombardi Comprehensive Cancer Center,
Abstract
A phase I/II study of carfilzomib, iberdomide (CC-220), and dexamethasone (KID) in patients with newly diagnosed transplant-eligible multiple myeloma.Org: John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ, Hackensack University Medical Center, Georgetown Lombardi Comprehensive Cancer Center, Center for Discovery and Innovation, Hackensack Meridian Health, Hackensack Meridian Health,
Abstract
A phase I dose escalation study of eryaspase in combination with modified FOLFIRINOX in locally advanced and metastatic pancreatic ductal adenocarcinoma.Org: Virginia Cancer Specialists, Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University Medical School, Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan,
Abstract
Associations between psychosocial risk factors and immune checkpoint inhibitor outcomes.Org: Center for Discovery and Innovation, Hackensack Meridian Health, Hackensack Meridian Health, Georgetown Lombardi Comprehensive Cancer Center, John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ, Innovation Center for Biomedical Informatics (ICBI),
Abstract
A phase IIb study of selinexor in combination with carfilzomib, daratumumab, or pomalidomide in patients with multiple myeloma relapsing on current therapy.Org: John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ, Hackensack University Medical Center, Georgetown Lombardi Comprehensive Cancer Center, Center for Discovery and Innovation, Hackensack Meridian Health, Hackensack Meridian Health,
Abstract
The roles of race and social determinants of health in pancreatic adenocarcinoma diagnosis and treatment.Org: Georgetown University Medical Center, Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Georgetown University Medical School,